Purpose - The main goal of this paper is to analyze the implementation of pharmaceuticals cost-containment measures in Egypt. Design/methodology/approach - This paper adopts descriptive and analytical techniques to assess the extent of implementing pharmaceutical cost-containment measures in...

Purpose - The research aims to investigate the factors influencing the adoption of artificial intelligence (AI) in pharmaceutical industry companies, specifically focusing on its impact on salesforce performance. Design/methodology/approach - We collected research data from pharmaceutical...

Background: This study examines the degree to which cognitive supply chain management (CSCM) indirectly enhances supply chain risk management (SCRM), addressing the lack of specific empirical research concerning the underlying mechanisms of this relationship. Specifically, this study tests the...

By extending the framework presented by Dosi et al. (2023b), we build an evolutionary agent-based model of the pharmaceutical sector featuring a government and a Public Research Lab investing in R&D and innovating across different therapeutic areas. After having empirically validated our...

Purpose: This study explores the barriers to adopting Industry 4.0 technologies within the pharmaceutical manufacturing sector. Despite the potential for transformative benefits, the sector has been slow in embracing these technologies due to unique regulatory and operational challenges. This...

Objectives: We investigate the long-run impact of changes in prescription drug sales on mortality and hospital utilization in Belgium during the first two decades of the 21st century. Methods: We analyze the correlation across diseases between changes in the drugs used to treat the disease and...

The Illumina/Grail case, which significantly rejected the EU Commission's wide interpretation of its powers of accepting a referral of a merger that did not meet the national merger control thresholds of the referring Member State, introduced changes in the EU about concentrations (Article 22 of...

• Around 60% of Irish net exports to US are pharma products. • A 200% US tariff would devastate all EU exports, not just Ireland's. • Irish business leaders we interviewed are confident that pharma's competitiveness will ensure its survival

This clustered Project Performance Assessment Report (PPAR) chapeau report synthesizes evaluation findings from six International Finance Corporation (IFC) investment projects in the pharmaceutical and life sciences sector, specifically targeting generic prescription drugs and consumer health...

Debt financing is important for financing major investments in the biopharmaceutical industry. Debt financing allows companies to raise funds without giving up ownership or control through indenture and covenants of the company. In this study, I analyze the effects of debt financing decisions on...

This study focuses on the precise forecasting of stock price movement to determine returns, diversify risk, and demystify existing opportunities. It also aims to gauge the difference in terms of the stock volatility of various pharma companies before and during the pandemic era. The prediction...

The pharmaceutical industry is a cornerstone of national economies and plays a critical role in public health. However, China's pharmaceutical industry faces significant challenges, including regional disparities in development. The existing research on operational efficiency evaluation...

Purpose: This study evaluates the success metrics of post-merger and acquisition (M&A) activities in the German biopharmaceutical industry, focusing on small- and medium-sized enterprises (SMEs). It examines how metrics such as economies of scale, economies of scope, market share, clinical...

Finding effective treatment for patients with rare diseases can be very difficult. Since the EU orphan regulations entered into force in 2000, it has played a central role in facilitating the development and authorisation of medicines for rare diseases.

This paper provides empirical evidence on which M&A deals spur innovation, and which stifle it. To do so, we consider not only the product market position of the acquiring firm, but also the position of both target and acquirer in the technology space. Focusing on the antidiabetic drugs market,...

This report outlines the threat of pharmaceutical crime in the EU and beyond, as assessed by Europol. It aims to raise awareness of the ways criminal networks exploit consumers and industry in generating illegal revenue through producing and selling counterfeit medicines.

The 340B Drug Pricing Program was instituted to bolster the health care safety net without relying on taxpayer money. It allows participating health care facilities - most of which are hospitals - to purchase drugs filled at in-house or contracted external pharmacies at discounts from...

This paper applies an empirical model of corporate capital structure, optimal debt, and overleveraging to estimate overleveraging measured as the difference between actual and optimal debt. Estimated using a sample of the twenty largest pharmaceutical firms, covering the time span from 2000 to...